Jerry Wang

Jerry (Li-Jie) Wang has years of experience in cancer biology and cell engineering fields for therapeutic applications in both academic and industrial settings after finishing their Ph.D. training in Taiwan.

Jerry completed a Ph.D. degree in Biomedical Science at Chang Gung University, Taiwan from 2009 to 2012 studying the mechanism of tumorigenesis between the innate immune system and EBV viral components in Nasopharyngeal Carcinoma. Jerry finished postdoctoral training at The Scripps Research Institute and Fred Hutchinson Cancer Research Center for studying protein synthesis control in processes of aging and tumor initiation. As the Senior Scientist at Seattle Children’s Research Institute and Synthego Corporation, he led T cell engineering projects to target autoimmune diseases via developing a CRISPR-based gene editing platform for preclinical applications.

Prior to joining Sonoma Biotherapeutics, Jerry was the senior scientist working on T cell engineering in preclinical research by developing CRISPR-based gene editing approaches at Synthego Corporation.

At Sonoma, Jerry works on the preclinical development of CAR-Treg products for targeting autoimmune diseases.